As with any method of meta-analysis, our analysis would be susceptible to publication biases, ie, linkage results being more likely to be published if they are positive. However, this bias is much less likely if only the results of whole-genome scans are included in our analysis of psychiatric disorders. This is because whole-genome scans are likely not to remain unpublished, even if they lack a significant

linkage. In omitting published evidence that are not from wholegenome scans, we are mindful that some true findings might be omitted from our analysis, such as the linkages Inhibitors,research,lifescience,medical to SZ reported separately on each arm of chromosome 6.25-29 Our simulations (not shown) indicate that results from different Inhibitors,research,lifescience,medical analytical methods can be combined so long as a particular result is not included on the basis of its http://www.selleckchem.com/products/BI6727-Volasertib.html significance. For the current study, we developed an objective hierarchy for choosing affection status model and analytical method, so that results of

each scan were not preferentially considered according to their P values. For comparison purposes, we present a table of meta-analysis results for all chromosomes for which Inhibitors,research,lifescience,medical at least one published genome scan had a P value <0.01 (Table I).30-51 For chromosome regions where the MSP<0.001, we present a “replication” MSP, where an MSP is calculated for that region, excluding the most significant study. Simulations show that the empirical P value of this statistic is equivalent to the nominal P value, ie, a replication MSP of 0.05 occurs ~ 1/20 times. The replication MSP statistic indicates whether the results of the MSP for all the studies are primarily due to a single significant study or whether other studies are also contributing.

Inhibitors,research,lifescience,medical For Inhibitors,research,lifescience,medical the analysis combining BP and SZ, the most significant BP study and the most significant SZ study are excluded from the replication MSP. Table I Meta-analysis of linkage data in published whole-genorne scans (as of October 2000). BP, bipolar rnanic depressive illness; SZ, schizophrenia; Loc, www.selleckchem.com/products/MDV3100.html location (in cM) of the locus with the most significant result from a single study in this region (location … These meta-analysis results strongly suggest that a statistically promising susceptibility locus for BP and a similarly promising susceptibility locus for SZ resides on the 13q chromosomal region. If the evidence for BP and SZ is combined, the GSK-3 data are consistent with the same regions on two chromosomes (13 and 22) and leads to the speculation that the same genes are conferring susceptibility to both illnesses.19,53-55 The data on chromosome 22, which are suggestive in themselves, are of increased interest because of deletions in the nearby chromosomal region that cause velocardiofacial syndrome (VCFS), which includes a high frequency of BP and SZ in the persons affected, as discussed below.